Immune Biosolutions announces the appointment of Nicholas Franco as Chairman of its Board of Directors
Immune Biosolutions is pleased to announce the appointment of Nicholas Franco as Chairman of its Board of Directors.
Mr. Franco brings extensive experience and strategic vision gained over a thirty-year international career in the pharmaceutical industry. He has held multiple key strategic roles within renowned organizations, including Executive Vice President and Head of Business Development at Actelion, acquired by J&J in 2017. Mr. Franco has also been responsible for global negotiations, Primary Care BD&L, Ophthalmology, and the Neuroscience Business Franchise at Novartis.
His expertise in business development, commercialization, and organizational leadership will play a crucial role in the growth and innovation of our company. His appointment demonstrates Immune Biosolutions‘ commitment to enriching its management and strengthening its market position.
Immune Biosolutions wishes to express his deepest gratitude to Ms. Louise Proulx for her unwavering commitment, insightful advice, and continuous collaboration during her tenure as chairperson of the board since 2019. Her involvement was crucial during the phase that saw the company transition from a service-oriented business to one developing its own immunotherapies. Ms Proulx will continue to play an active role on the company’s board of directors.
« I’m very honored by the trust of the other members of the Board and of the company leadership in nominating me as chairman. Immune Biosolutions is at a very interesting point in its development and value maximization of its technology and immunotherapies. Over the last year as a member of the Board, I have seen a significant progress in the strategy of the company that augurs well for its future. With the other members of the Board, I will do all that I can to ensure that happens. » – Nicholas Franco.
« It is with great pleasure that I welcome Nicholas as the new Chairman of our Board of Directors. I look forward to benefiting from his insightful leadership, strategic vision, and ability to inspire excellence within our team. I am confident that his experience and dynamic leadership will be a driving force for positive change within our organization. » – Luc Paquet, CEO of Immune Biosolutions.
About Immune Biosolutions
Immune Biosolutions is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development.
